In the Journals

ANCHOR, MARINA and HORIZON trials show mixed visual outcomes at 7 years

One-third of patients who participated in the ANCHOR and MARINA trials had good visual outcomes and one-third had poor visual outcomes at about 7 years, according to a study.

The Seven-Year Observational Update of Macular Degeneration Patients Post-MARINA/ANCHOR and HORIZON Trials (SEVEN-UP study) included 65 patients with exudative age-related macular degeneration who underwent intensive Lucentis (ranibizumab, Genentech) therapy in one of the trials.

Investigators assessed Snellen best corrected visual acuity, change in letter scores and anatomic outcomes.

Mean follow-up was 7.3 years after entry into the ANCHOR or MARINA trial and 3.4 years after completion of the HORIZON trial.

For the ANCHOR and MARINA trials, BCVA was 20/70 or better in 37% of eyes and 20/40 or better in 23% of eyes. BCVA was 20/200 or worse in 37% of eyes.

Letter scores were stable or improved in 43% of eyes compared with baseline measurements from ANCHOR and MARINA. Scores decreased by 15 letters or more in 34% of eyes; the mean decrease was 8.6 letters (P < .005).

Eyes had received a mean 6.8 ranibizumab injections for a mean duration of 3.4 years after exiting the HORIZON trial. Gains in letter scores were significantly higher in patients who received 11 or more injections after exiting the HORIZON trial (P < .05).

Macular atrophy was identified on fundus autofluorescence in 57 of 58 eyes (98%). The association between area of atrophy and poor visual outcome was significant (P < .0001).

Disclosure: See the study for a full list of the authors’ relevant financial disclosures.

One-third of patients who participated in the ANCHOR and MARINA trials had good visual outcomes and one-third had poor visual outcomes at about 7 years, according to a study.

The Seven-Year Observational Update of Macular Degeneration Patients Post-MARINA/ANCHOR and HORIZON Trials (SEVEN-UP study) included 65 patients with exudative age-related macular degeneration who underwent intensive Lucentis (ranibizumab, Genentech) therapy in one of the trials.

Investigators assessed Snellen best corrected visual acuity, change in letter scores and anatomic outcomes.

Mean follow-up was 7.3 years after entry into the ANCHOR or MARINA trial and 3.4 years after completion of the HORIZON trial.

For the ANCHOR and MARINA trials, BCVA was 20/70 or better in 37% of eyes and 20/40 or better in 23% of eyes. BCVA was 20/200 or worse in 37% of eyes.

Letter scores were stable or improved in 43% of eyes compared with baseline measurements from ANCHOR and MARINA. Scores decreased by 15 letters or more in 34% of eyes; the mean decrease was 8.6 letters (P < .005).

Eyes had received a mean 6.8 ranibizumab injections for a mean duration of 3.4 years after exiting the HORIZON trial. Gains in letter scores were significantly higher in patients who received 11 or more injections after exiting the HORIZON trial (P < .05).

Macular atrophy was identified on fundus autofluorescence in 57 of 58 eyes (98%). The association between area of atrophy and poor visual outcome was significant (P < .0001).

Disclosure: See the study for a full list of the authors’ relevant financial disclosures.